Showing results (331-340 of 441) with videos related to
Sort By:
Pageof 45
International Journal of Radiation Oncology, Biology, Physics|August 31, 2010
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphomaNadia N Laack, Brian Patrick O'Neill, Karla V Ballman, et al.Neuro-Oncology|December 15, 2010
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaJohn H Sampson, Kenneth D Aldape, Gary E Archer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium studyJohn F de Groot, Kathleen R Lamborn, Susan M Chang, et al.Neuro-Oncology Advances|October 1, 2025
Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axisSeketoulie Keretsu, Taijun Hana, Alexander Lee, et al.Journal of Neuro-Oncology|January 25, 2017
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomasLakshmi Nayak, John de Groot, Jeffrey S Wefel, et al.Frontiers in Oncology|February 6, 2023
Heterogeneous clinicopathological findings and patient-reported outcomes in adults with MN1-altered CNS tumors: A case report and systematic literature reviewStephen C Frederico, Elizabeth Vera, Zied Abdullaev, et al.Neuro-Oncology Advances|February 4, 2022
A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell linesAshish H Shah, Robert Suter, Pavan Gudoor, et al.Neuro-Oncology Practice|November 17, 2022
Exploring the prevalence and burden of sleep disturbance in primary brain tumor patientsAmanda L King, Dorela D Shuboni-Mulligan, Elizabeth Vera, et al.JCI Insight|September 20, 2019
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNKAmber J Giles, Shuyu Hao, Michelle Padget, et al.Oncotarget|June 18, 2020
Efficacy of osimertinib against EGFRvIII+ glioblastomaGustavo Chagoya, Shawn G Kwatra, Cory W Nanni, et al.Pageof 45